Scientific Steering Committee

triMS.online will allow for idea exchange on a global basis, particularly for individuals who are not often able to travel for scientific meetings

Laura Airas

triMS.online will help young neurologists and researchers to overcome barriers that often limit their ability to attend conferences

 

gavin

Gavin Giovannoni

Chair of Neurology, Barts and The London School of Medicine and Dentistry, UK and founder of triMS.online

Professor Giovannoni’s research is focused on
Epstein-Barr virus as a possible cause of MS,
MS-related neurodegeneration, biomarker
discovery, MS clinical outcome measures, MS
clinical trials and immune tolerance strategies.

laura

Laura Airas

Professor of Neuroimmunology, University of Turku, Finland

Professor Airas’s main interest is in pathological mechanisms of progressive MS. She was among the first in the world to apply PET imaging to the study of neuroinflammation in MS.

Reem Bunyan_edited_square for website

Reem Bunyan

CEO, Center for Improving Value in Health,
Saudi Arabia

Dr Bunyan is an expert in paediatric MS.
She completed a clinical fellowship in MS
and autoimmune neurology at the Mayo Clinic, USA, and was National Lead of the Chronic Disease System of Care and Director of the Model of Care in E1 Cluster in Saudi Arabia. Dr Bunyan’s main interest is the enhancement of the national health system in Saudi Arabia to improve health and healthcare.

Dr Juzar Hooker photo_square for website

Juzar Hooker

Consultant Neurologist, Clinical Teacher and Honorary
Faculty, Aga Khan University Hospital, Nairobi, Kenya

Dr Hooker’s interests include movement
disorders, neurodegenerative diseases,
neurological infections and neuroinflammatory disorders, with a focus on MS. He is taking part in a research collaboration that aims to characterize the population of patients with MS at Aga Khan University Hospital and is also involved in setting up a local registry of patients with MS.

noriko

Noriko Isobe

Professor and Chairperson, Department of Neurology, Kyushu University, Japan

Dr Isobe’s current research interests include genetic susceptibility to MS, genetic determinants of disease progression in MS and T-cell receptor repertoires in MS.

Kalincik

Tomas Kalincik

Associate Professor and Head, Clinical Outcomes Research Unit, University of Melbourne, Australia and Head of the Royal Melbourne Hospital MS Centre, Australia

Professor Kalincik’s research uses advanced statistical methods to study outcomes in MS and neuromyelitis optica, individualized therapy, prognostics, epidemiology and utility of volumetric magnetic resonance imaging.

arrah Mateen; Bulfinch 045; Formal Portrait

Farrah Mateen

Associate Professor of Neurology, Harvard Medical School, MA, USA

Dr. Mateen leads a clinical trial funded by the National MS Society on MS medication adherence. Currently, she is the principal
investigator of several multi-country studies.

jiwon

Jiwon Oh

Medical Director, Barlo Multiple Sclerosis Program
Staff Neurologist, St. Michael’s Hospital
Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute
Assistant Professor, Division of Neurology, University of Toronto, Canada

Dr Oh’s research focuses on developing
advanced MRI techniques in the spinal cord
and brain for use in clinical settings. She is
leading the Canadian National Progression
Cohort, a prospective cohort study
investigating progression in MS.

professional photo 2020 - Julia

Julia Pakpoor

Trainee Neurologist and Researcher, Oxford University Hospitals, UK

Dr Pakpoor’s research is focused on using population-based data to explore risk factors for MS and the burden of neurodegenerative diseases on the health service.

saul

Saúl Reyes Niño

Chair of Neurology, Fundación Santa Fe de Bogotá, Colombia
Honorary Clinical Lecturer, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK

Dr Reyes’ research is focused on vaccination strategies in MS, the role of neurofilaments in clinical practice and the impact of social capital on the health outcomes of people with MS.